Published in:
Open Access 01-12-2017 | Erratum
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Published in: Journal of Hematology & Oncology | Issue 1/2017
Login to get accessExcerpt
The original article [1] contains an error whereby Fig. 2a & b are mistakenly interchanged and contain incorrect colour-coding.
Fig. 2:
Survival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b). Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE not evaluable
× ![]()
…